Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04028-z
Abstract: Ruxolitinib is a targeted drug to treat myelofibrosis (MF). Ruxolitinib has significant advantages in spleen reduction and increasing 5-year overall survival (OS), and ruxolitinib-based combinations might provide more benefits than ruxolitinib monotherapy. In this review,… read more here.
Keywords: myelofibrosis; based combinations; treatment related; ruxolitinib based ... See more keywords
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
Sign Up to like & getrecommendations! Published in 2022 at "Blood Cancer Journal"
DOI: 10.1038/s41408-021-00603-3
Abstract: Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of survival of AML harboring MLL1 re-arrangement (r) and FP, or expressing mutant… read more here.
Keywords: menin inhibitor; menin; based combinations; inhibitor ... See more keywords
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Expert Review of Precision Medicine and Drug Development"
DOI: 10.1080/23808993.2024.2330422
Abstract: ABSTRACT Background Radiological response assessment is becoming challenging with novel immune-based combinations for metastatic renal cell carcinoma (mRCC). RECIST criteria appear not exhaustively adequate to capture the kinetics of treatment response, which is better reflected… read more here.
Keywords: combinations metastatic; metastatic renal; immune based; response ... See more keywords
A Combinatorial Functional Precision Medicine Platform to Evaluate Immunotherapy-Based Combinations in Non-Hodkin Lymphoma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210510
Abstract: PURPOSE: Non-Hodgkin lymphoma (NHL) is a heterogenous malignancy with many different subtypes. Although patients initially respond to treatments, approximately 40% of this cohort will subsequently relapse. Beyond second-line salvage regimen, determining the next option is… read more here.
Keywords: immunotherapy; culture; drug; cell ... See more keywords
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2021-0841
Abstract: Aims: Immune checkpoint inhibitors (ICIs) have recently revolutionized the treatment landscape of metastatic urothelial carcinoma. The authors performed a meta-analysis aiming to evaluate the predictive value of Eastern Cooperative Oncology Group performance status, age, sex,… read more here.
Keywords: oncology; urothelial carcinoma; based combinations; meta analysis ... See more keywords
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence.
Sign Up to like & getrecommendations! Published in 2021 at "Immunotherapy"
DOI: 10.2217/imt-2020-0323
Abstract: The last three decades have witnessed a revolution in the therapeutic scenario of metastatic renal cell carcinoma (mRCC), due to the advent of novel agents including tyrosine kinase inhibitors, immune checkpoint inhibitors and the combination of… read more here.
Keywords: first line; treatment; metastatic renal; immune based ... See more keywords
Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0261
Abstract: Aims: We performed a meta-analysis to investigate the predictive value of PD-L1 in metastatic renal cell carcinoma (mRCC) patients receiving immune-based combinations versus sunitinib monotherapy. Materials & Methods: Outcomes of interest included OS and PFS;… read more here.
Keywords: meta analysis; mrcc; assessing status; based combinations ... See more keywords
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.562558
Abstract: The past decade has witnessed major advances in our understanding of molecular biology, which led to breakthrough novel therapies, importantly including the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax. Notably, venetoclax-based combinations have improved outcomes, including both… read more here.
Keywords: venetoclax based; myeloid leukemia; combinations acute; acute myeloid ... See more keywords
New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14235868
Abstract: Simple Summary In this review, we detail the data on a new treatment of hepatocellular carcinoma. A new combination of therapies, based on immunotherapy, has recently emerged as efficacious treatment. While being very interesting for… read more here.
Keywords: immunotherapy based; first line; line; based combinations ... See more keywords
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Current Oncology"
DOI: 10.3390/curroncol30010057
Abstract: Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival… read more here.
Keywords: based combinations; rate; immune based; meta analysis ... See more keywords